Durability of the first antiretroviral treatment regimen and reasons for change in patients with HIV infection

HIV Clinical Trials

Volumn 15, Issue 1, 2014, Pages 27-35

  De La Torre Lima, Javier ^a   Aguilar, Ana ^a   Santos, Jesus ^b   Jiménez Oñate, Francisco ^c   Marcos, Miguel ^a   Núñez, Victoria ^a   Olalla, Julian ^a   Del Arco, Alfonso ^a   Prada, Jose ^a  

^a HOSPITAL COSTA DEL SOL   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

antiretroviral treatment; durability; HIV infection; side effects; toxicity

Indexed keywords

ANTIRETROVIRAL TREATMENT; DURABILITY; HIV INFECTION; SIDE EFFECTS; TOXICITY;

ADULT; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84894173845     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1501-27     Document Type: Article

References (29)

1. Murphy EL Collier AC Kalish LA et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135(1):17-26. (Pubitemid 32619279)
2. Palella FJ Jr Delaney KM Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-860. (Pubitemid 28135961)
3. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)]. Enferm Infecc Microbiol Clin. 2012;30(6):e1-89.
4. Mocroft A Vella S Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352(9142): 1725-1730.
5. Mocroft A Youle M Moore A et al. Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre. AIDS. 2001;15(2):185-194. (Pubitemid 32142293)
6. De La Torre J Santos J Perea-Milla E et al. Primera pauta de tratamiento antirretroviral en pacientes con infeccion por el VIH. Durabilidad y factores asociados a su modifi- cacion. Enferm Infecc Microbiol Clin. 2008;26(7):416-422.
7. Bae JW Guyer W Grimm K Altice FL. Medication persistence in the treatment of HIV infection: A review of the literature and implications for future clinical care and research. AIDS. 2011;25(3):279-290.
8. Martin MT Rovira M Massanes M et al. Analisis de la duracion y los motivos de cambio de la primera combinacion de tratamiento antirretroviral. Farm Hosp. 2010;34(5):224-230.
9. Chen RY Westfall AO Mugavero MJ et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis. 2003;37(5):714-722. (Pubitemid 37100815)
10. Willig JH Abroms S Westfall AO et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS. 2008;22(15):1951-1960.
11. Vo TT Ledergerber B Keiser O et al. Durability and outcome of initial antiretroviral treatments received during2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis. 2008;197(12):1685-1694. (Pubitemid 351919632)
12. Abgrall S; The Antiretroviral Therapy Cohort Collaboration (ART-CC). Durability of first ART regimen and risk factors for modification interruption or death in HIV-positive patients starting ART in Europe and N. America 2002-2009. AIDS. 2013;27:803-813.
13. Elzi L Marzolini C Furrer H et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170(1):57-65.
14. Ledergerber B Cavassini M Battegay M et al. Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Med. 2011;12(5):279-288.
15. Smit M Smit C Cremin I Garnett GP Hallett T de WF. Could better tolerated HIV drug regimens improve patient outcome? AIDS. 2012;26(15):1953-1959.
16. Juday T Grimm K Zoe-Powers A Willig J Kim E. A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States. AIDS Care. 2011;23(9):1154-1162.
17. Di Biagio A Prinapori R Giannarelli D et al. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. J Antimicrob Chemother. 2013;68(1):200-205.
18. Maggiolo F Arici C Airoldi M et al. Reasons for discontinuation of nevirapine-containing HAART: Results from an unselected population of a large clinical cohort. J Antimicrob Chemother. 2007;59(3):569-572. (Pubitemid 47073469)
19. Reekie J Reiss P Ledergerber B et al. A comparison of the long-Term durability of nevirapine efavirenz and lopinavir in routine clinical practice in Europe: A EuroSIDA study. HIV Med. 2011;12(5):259-268.
20. d'Arminio MA Lepri AC Rezza G et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14(5):499-507. (Pubitemid 30209692)
21. Jarrin I Hernandez-Novoa B Alejos B et al. Persistence of novel first-line antiretroviral regimes in a cohort of HIVpositive subjects CoRIS 2008-2010 [published online ahead of print September 20 2012]. Antivir Ther.
22. Prosperi MC Fabbiani M Fanti I et al. Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: A retrospective cohort study. BMC Infect Dis. 2012;12:296.
23. Yuan Y L'italien G Mukherjee J Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med.2006;7(3):156-162. (Pubitemid 43337594)
24. Cicconi P Cozzi-Lepri A Castagna A et al. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med. 2010;11(2):104-113.
25. Robison LS Westfall AO Mugavero MJ et al. Short-Term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses.2008;24(11):1347-1355.
26. Park WB Choe PG Kim SH et al. Early modification of initial HAART regimen associated with poor clinical outcome in HIV patients. AIDS Res Hum Retroviruses.2007;23(6):794-800.
27. Ribeiro FA Tupinambas U Fonseca MO Greco DB. Durability of the first combined antiretroviral regimen in patients with AIDS at a reference center in Belo Horizonte Brazil from 1996 to 2005. Braz J Infect Dis. 2012;16(1):27-33.
28. Domingo P Suarez-Lozano I Torres F et al. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: The SUSKA study a nonrandomized comparison from the VACH cohort. J Antimicrob Chemother. 2008;61(6):1348-1358. (Pubitemid 351753607)
29. Willig JH Aban I Nevin CR et al. Darunavir outcomes study: Comparative effectiveness of virologic suppression regimen durability and discontinuation reasons for threeclass experienced patients at 48 weeks. AIDS Res Hum Retroviruses. 2010;26(12):1279-1285